WEBHELP
20.12.2022 15:02:09 CET | Business Wire | Press release
Webhelp, a leading global customer experience BPO player, has announced that this year it has achieved its highest global growth since inception, with operations now spanning more than 60 countries and with close to 125,000 people employed globally. Webhelp also won more than 50 industry awards this year, was recognized as a leader in the Gartner Magic Quadrant for Customer Service BPO, and earned top ratings in Customer Experience globally by Analyst Everest Group.
Across the year, Webhelp expanded in 24 new locations and six new countries – Thailand, Bosnia Herzegovina, Ghana, Israel, North Macedonia, and China – with a further 18 new site openings in existing locations across the United States, Latin America, Asia Pacific, and Europe, Middle East and Africa. Webhelp also experienced very strong client growth in 2022, onboarding over 240 new logo clients across the world, and welcoming more than 25,000 game-changers to the company. In line with increased demand, Webhelp continued to bolster hybrid and remote working through its Webhelp Anywhere proposition to deliver ultimate flexibility and scalability to clients and meet evolving employee work preferences.
“Growth is a team sport, and every single one of our people has had a part to play in this extraordinary year for Webhelp. We pride ourselves on the stellar work our game-changers deliver on behalf of our clients and look forward to continuing this trend in 2023, investing further in tech and people, to continue to provide the best possible solutions to our clients and their customers,” said Olivier Duha, CEO and Co-Founder of Webhelp.
Webhelp successfully completed a number of notable acquisitions and strategic investments, including the acquisition of Grupo Services in LATAM, the leading Brazilian providers of digitally enabled Customer Experience. In EMEA, Webhelp also joined forces with Uitblinqers to strengthen its position in the Dutch market and made additional investments with Gobeyond Partners, with the creation of a Nudge practice – a strategic unit that leverages behavioral economics to help organizations drive the best possible outcomes, through influencing customer behaviors.
“The past few years have taught us that connection and humanity are more important than ever. I’m incredibly proud to be at the helm of a fast-growing company that is leading the way in tech-enabled, human-centric Customer Experience,” continues Olivier Duha.
Webhelp has also been focusing on strengthening its sustainability and environmental social governance (ESG) practices. 12% of its workforce have been hired via an award-winning impact sourcing program, which includes hiring disadvantaged youth, reintegration initiatives to help female prisoners get into work, and an ecosystem that supports migrant and refugee employability. This year, Webhelp also partnered with SGS, the leading certification company, on a long-term initiative to safeguard frontline health and well-being.
Webhelp’s growth strategy underpins its desire to serve as a strategic blue ocean partner, leveraging a combination of global reach and hyper local expertise to unlock new value for its clients. Webhelp’s solutions and services are designed to be relevant and valuable for both digital native clients and businesses seeking to transform CX and drive strategic value and differentiation from it.
In 2023, Webhelp will continue its strategic growth, expanding further in new and current key locations across the world, including APAC, EMEA, and the Americas, as well as investments in people, technology, and innovation.
###
About Webhelp
Webhelp designs, delivers, and optimizes unforgettable human experiences for today’s digital world – creating game-changing customer journeys. From sales to service, content moderation to credit management, Webhelp is an end-to-end partner across all B2C and B2B customer journeys. Its over 110,000 passionate employees across more than 60 countries thrive on making a difference for the world’s most exciting brands. Webhelp is currently owned by its management and Groupe Bruxelles Lambert (Euronext: GBLB), a leading global investment holding, as of November 2019. For more information on Webhelp, visit Webhelp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005345/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
